中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (10): 988-991.doi: 10.35541/cjd.20260362

• 研究报道 • 上一篇    下一篇

2022—2024年全国淋病奈瑟菌耐药监测点药物敏感试验室间质评结果分析

戴秀芹    朱小宇    奚悦    徐文绮      

  1. 中国医学科学院北京协和医学院,皮肤病研究所  中国疾病预防控制中心性病控制中心性病参比实验室,南京  210042
  • 收稿日期:2026-07-01 修回日期:2026-09-02 发布日期:2026-10-07
  • 通讯作者: 戴秀芹 E-mail:daixiuqin@126.com

Analysis of external quality assessment results of antimicrobial susceptibility testing at national surveillance sites for Neisseria gonorrhoeae antimicrobial resistance from 2022 to 2024

Dai Xiuqin, Zhu Xiaoyu, Xi Yue, Xu Wenqi   

  1. Reference Laboratory of STD, National Center for STD Control, Chinese Center for Disease Control and Prevention, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
  • Received:2026-07-01 Revised:2026-09-02 Published:2026-10-07
  • Contact: Dai Xiuqin E-mail:daixiuqin@126.com

摘要: 【摘要】 目的 分析全国淋病奈瑟菌(淋球菌)耐药监测点实验室药物敏感试验检测质量。方法 中国疾病预防控制中心性病控制中心在2022—2024年间每年向20家国家级淋球菌耐药监测点发放3株淋球菌盲样考核样本和7种抗菌药物粉剂(青霉素、环丙沙星、大观霉素、四环素、头孢曲松、阿奇霉素及头孢克肟),监测点实验室以琼脂稀释法进行药物敏感性检测,回报检测结果。如考核样本的最低抑菌浓度值在参考值 ± 1个浓度范围内,则评定为符合,评估回报结果的符合率。此外,还进行产青霉素酶淋球菌检测,根据所有样本检测的符合情况评定考核结果。结果 2022—2024年间收到回报结果168份,总体回报率93.3%;各年度参评单位数分别为19、19、18,考核合格数分别为16(84.2%)、18(94.7%)、18(100%),总体合格率92.9%。抗菌药物敏感试验3年总体符合率由高到低顺序为大观霉素(166份,98.8%)、四环素(163份,97.0%)、环丙沙星(151份,89.9%)、阿奇霉素(149份,88.7%)、青霉素(147份,87.5%)、头孢克肟(143份,85.1%)及头孢曲松(139份,82.7%),质粒介导的高度四环素耐药检测符合率为100.0%,产青霉素酶淋球菌检测符合率96.4%。在3年监测期间,青霉素、头孢曲松、环丙沙星、大观霉素、阿奇霉素及头孢克肟的符合率呈上升趋势,质粒介导的产青霉素淋球菌符合率呈现下降趋势,四环素符合率则呈现波动。结论 3年间全国淋球菌耐药监测点实验室对青霉素、头孢曲松、环丙沙星、大观霉素、阿奇霉素及头孢克肟的药物敏感试验检测质量呈稳步提升。

关键词: 淋病奈瑟球菌, 抗药性, 耐药监测, 药物敏感试验, 室间质量评价

Abstract: 【Abstract】 Objective To analyze the quality of antimicrobial susceptibility testing in laboratories at national surveillance sites for Neisseria gonorrhoeae antimicrobial resistance. Methods From 2022 to 2024, the National Center for STD Control, Chinese Center for Disease Control and Prevention annually distributed blinded proficiency testing panels to 20 national Neisseria gonorrhoeae antimicrobial resistance surveillance sites. Each panel comprised 3 coded Neisseria gonorrhoeae isolates and standard powders of 7 antimicrobial agents (penicillin, ciprofloxacin, spectinomycin, tetracycline, ceftriaxone, azithromycin, and cefixime). Sentinel site laboratories performed antimicrobial susceptibility testing by the agar dilution method and reported the test results to the National Center for STD Control. If the minimum inhibitory concentration (MIC) of a proficiency test isolate was within ± 1 two-fold dilution of the reference MIC, the result was considered concordant, and the concordance rate was calculated accordingly. In addition, penicillinase-producing Neisseria gonorrhoeae was also tested, and the assessment results were rated according to the concordance of results across all sample tests. Results From 2022 to 2024, a total of 168 result reports were received, with an overall reporting rate of 93.3%; the numbers of participating laboratories in the above years were 19, 19, and 18, respectively; the numbers of qualified laboratories were 16 (84.2%), 18 (94.7%) and 18 (100%), respectively, with an overall pass rate of 92.9%. The overall 3-year concordance rates of antimicrobial susceptibility testing, in descending order, were as follows: 98.8% for spectinomycin (166 reports), 97.0% for tetracycline (163 reports), 89.9% for ciprofloxacin (151 reports), 88.7% for azithromycin (149 reports), 87.5% for penicillin (147 reports), 85.1% for cefixime (143 reports), and 82.7% for ceftriaxone (139 reports); the concordance rate of plasmid-mediated high-level tetracycline resistance testing was 100.0%, and that of penicillinase-producing Neisseria gonorrhoeae testing was 96.4%. During the 3-year surveillance period, the concordance rates of penicillin, ceftriaxone, ciprofloxacin, spectinomycin, azithromycin, and cefixime testing showed an upward trend, the concordance rate of plasmid-mediated penicillinase-producing Neisseria gonorrhoeae testing showed a downward trend, and that of tetracycline testing fluctuated. Conclusion During the 3-year surveillance period, the sentinel site laboratories showed steady improvement in the quality of antimicrobial susceptibility testing for penicillin, ceftriaxone, ciprofloxacin, spectinomycin, azithromycin, and cefixime.

Key words: Neisseria gonorrhoeae, Drug resistance, Drug resistance surveillance, Drug susceptibility test, External quality assessment

引用本文

戴秀芹 朱小宇 奚悦 徐文绮. 2022—2024年全国淋病奈瑟菌耐药监测点药物敏感试验室间质评结果分析[J]. 中华皮肤科杂志, 2026,59(10):988-991. doi:10.35541/cjd.20260362

Dai Xiuqin, Zhu Xiaoyu, Xi Yue, Xu Wenqi. Analysis of external quality assessment results of antimicrobial susceptibility testing at national surveillance sites for Neisseria gonorrhoeae antimicrobial resistance from 2022 to 2024[J]. Chinese Journal of Dermatology, 2026, 59(10): 988-991.doi:10.35541/cjd.20260362